Cerus Corp (CERS) Stock Price, Quote & News

Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets an...

Industry: Medical Devices

Sector: Healthcare

Phone: 925 288 6000

Website: www.cerus.com

Address:

1220 Concord Avenue, Suite 600, Concord, United States

CrossAsset Dec. 25 at 3:15 PM

$CERS Market behavior suggests the name is transitioning from speculation toward proof‑based evaluation. Sequential improvement must start appearing across core metrics. Consistent milestones could shift perception faster than fundamentals alone. The next phase will be defined less by vision and more by delivery.

0 · Reply

huma_44 Dec. 24 at 3:01 PM

$CERS added more at 2.03

0 · Reply

bobmoney Dec. 23 at 10:53 PM

$CERS best blood treatment... surprised a big pharma has not acquired CERS...

0 · Reply

huma_44 Dec. 23 at 7:35 PM

$CERS added

0 · Reply

BullMaven Dec. 22 at 4:51 PM

$CERS very undervalued. no brainer to add at this level. expect 5+ at leadt by mid summer

0 · Reply

N8LongShort Dec. 18 at 5:29 PM

$CERS when i max my 401(k) in january im averaging up

0 · Reply

N8LongShort Dec. 18 at 11:27 AM

$CERS

0 · Reply

OldManLogan Dec. 17 at 8:14 PM

$CERS Of the $400M in market cap, 75% is owned by insiders and institutions... that just leaves $100M for everyone else... well, I'd like a million, so 99M for everyone else, lol!

0 · Reply

N8LongShort Dec. 17 at 7:52 PM

$CERS 2.20-2.50 is the resistance area once we work past that itll be a nice path for us

0 · Reply

VolumePrice Dec. 17 at 6:21 PM

$CERS added 2k

0 · Reply

Cerus Corporation Announces Group Purchasing Agreement with Blood Centers of America

Nov 23, 2025, 11:07 PM EST - 4 weeks ago

Cerus: IFC Growth And RBC Optionality

Nov 6, 2025, 7:06 PM EST - 6 weeks ago

Cerus Corporation (CERS) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:01 PM EST - 6 weeks ago

Cerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance

Oct 21, 2025, 8:30 AM EDT - 2 months ago

Cerus Corporation Announces Abstracts and Industry Workshop on IFC at the 2025 AABB Annual Meeting

Oct 16, 2025, 4:00 PM EDT - 2 months ago

Cerus Corporation to Release Third Quarter 2025 Financial Results on November 6, 2025

Aug 25, 2025, 9:00 AM EDT - 4 months ago

The German National Blood Advisory Committee Issues Formal Recommendation for Improving the Safety of Platelet Transfusions

Aug 21, 2025, 8:30 AM EDT - 4 months ago

Cerus Corporation to Participate in the Cantor Global Healthcare Conference 2025

Aug 5, 2025, 9:02 PM EDT - 5 months ago

Cerus Corporation (CERS) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:01 PM EDT - 5 months ago

Cerus Corporation Announces Second Quarter 2025 Financial Results

Jul 22, 2025, 4:15 PM EDT - 5 months ago

Cerus Corporation to Release Second Quarter 2025 Financial Results on August 5, 2025

Jul 21, 2025, 8:30 AM EDT - 5 months ago

Cerus Corporation Announces Additional Department of Defense Award to Advance Care for Major Hemorrhage in Traumatic Injury

Jul 2, 2025, 8:30 AM EDT - 6 months ago

Cerus Corporation Provides INTERCEPT Red Blood Cell CE Mark Application Update

Jun 13, 2025, 4:01 PM EDT - 6 months ago

Cerus Corporation Celebrates World Blood Donor Day 2025

Jun 3, 2025, 4:30 PM EDT - 7 months ago

Cerus Corporation to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 29, 2025, 8:30 AM EDT - 7 months ago

Cerus Corporation Presents Clinical Data for INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion Congress in Milan

May 28, 2025, 8:30 AM EDT - 7 months ago

Cerus Corporation Announces Multiple In-Country Regulatory Approvals for INT200 – Next-Generation INTERCEPT Illumination Device

May 1, 2025, 8:26 PM EDT - 8 months ago

Cerus Corporation (CERS) Q1 2025 Earnings Call Transcript

May 1, 2025, 4:00 PM EDT - 8 months ago

Cerus Corporation Announces First Quarter 2025 Financial Results

Apr 17, 2025, 8:30 AM EDT - 9 months ago

Cerus Corporation to Release First Quarter 2025 Financial Results on May 1, 2025

Mar 5, 2025, 1:00 PM EST - 10 months ago

Cerus Corporation Announces Receipt of CE Mark for Next-Generation INTERCEPT Illumination Device (INT200)

Feb 20, 2025, 9:50 PM EST - 10 months ago

Cerus Corporation (CERS) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 4:00 PM EST - 10 months ago

Cerus Corporation Announces Full-Year and Fourth Quarter 2024 Financial Results

Feb 19, 2025, 4:00 PM EST - 11 months ago

Cerus Corporation to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 7, 2025, 8:30 AM EST - 11 months ago

Cerus Corporation to Release Fourth Quarter and Full-Year 2024 Financial Results on February 20, 2025

Jan 13, 2025, 8:30 AM EST - 1 year ago

Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2024 Product Revenue and Provides Business Update

Nov 13, 2024, 8:30 AM EST - 1 year ago

Cerus Corporation to Participate in Upcoming Investor Conferences

Oct 30, 2024, 11:52 PM EDT - 1 year ago

Cerus Corporation (CERS) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 4:00 PM EDT - 1 year ago

Cerus Corporation Announces Third Quarter 2024 Financial Results

Oct 18, 2024, 8:30 AM EDT - 1 year ago

Cerus Corporation to Release Third Quarter 2024 Financial Results on October 30, 2024

Oct 18, 2024, 8:30 AM EDT - 1 year ago

Cerus Corporation Announces Workshop and Abstracts at the 2024 AABB Annual Meeting

Oct 16, 2024, 4:00 PM EDT - 1 year ago

Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe

Aug 1, 2024, 8:29 PM EDT - 1 year ago

Cerus Corporation (CERS) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:00 PM EDT - 1 year ago

Cerus Corporation Announces Second Quarter 2024 Financial Results and Increases Full-Year 2024 Product Revenue Guidance Range

Jul 18, 2024, 8:30 AM EDT - 1 year ago

Cerus Corporation to Release Second Quarter 2024 Financial Results on August 1, 2024

Jul 2, 2024, 4:00 PM EDT - 1 year ago

Cerus Corporation Announces Appointment of Dean Gregory to Board of Directors

Jun 21, 2024, 8:30 AM EDT - 1 year ago

Cerus Corporation Announces Symposium and Abstracts at the 38th International Congress of the International Society of Blood Transfusion

Jun 14, 2024, 8:30 AM EDT - 1 year ago

Cerus Corporation Celebrates World Blood Donor Day 2024

May 22, 2024, 8:30 AM EDT - 1 year ago

Cerus Corporation to Participate in 21st Annual Craig-Hallum Institutional Investor Conference

May 2, 2024, 7:37 PM EDT - 1 year ago

Cerus Corporation (CERS) Q1 2024 Earnings Call Transcript

May 2, 2024, 4:00 PM EDT - 1 year ago

Cerus Corporation Announces First Quarter 2024 Financial Results

Apr 18, 2024, 8:30 AM EDT - 1 year ago

Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024

Mar 26, 2024, 8:30 AM EDT - 1 year ago

Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life

Mar 19, 2024, 8:00 AM EDT - 1 year ago

Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients

Mar 5, 2024, 6:43 PM EST - 1 year ago

Cerus Corporation (CERS) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 4:00 PM EST - 1 year ago

Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results

Feb 20, 2024, 8:30 AM EST - 2 years ago

Cerus Corporation to Release Fourth Quarter and Full-Year 2023 Financial Results on March 5, 2024

Jan 8, 2024, 8:30 AM EST - 2 years ago

Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2023 Product Revenue and Provides Business Update

Nov 2, 2023, 10:52 PM EDT - 2 years ago

Cerus Corporation (CERS) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 4:00 PM EDT - 2 years ago

Cerus Corporation Announces Third Quarter 2023 Financial Results

CrossAsset Dec. 25 at 3:15 PM

0 · Reply

huma_44 Dec. 24 at 3:01 PM

$CERS added more at 2.03

0 · Reply

bobmoney Dec. 23 at 10:53 PM

$CERS best blood treatment... surprised a big pharma has not acquired CERS...

0 · Reply

huma_44 Dec. 23 at 7:35 PM

$CERS added

0 · Reply

BullMaven Dec. 22 at 4:51 PM

$CERS very undervalued. no brainer to add at this level. expect 5+ at leadt by mid summer

0 · Reply

N8LongShort Dec. 18 at 5:29 PM

$CERS when i max my 401(k) in january im averaging up

0 · Reply

N8LongShort Dec. 18 at 11:27 AM

$CERS

0 · Reply

OldManLogan Dec. 17 at 8:14 PM

$CERS Of the $400M in market cap, 75% is owned by insiders and institutions... that just leaves $100M for everyone else... well, I'd like a million, so 99M for everyone else, lol!

0 · Reply

N8LongShort Dec. 17 at 7:52 PM

$CERS 2.20-2.50 is the resistance area once we work past that itll be a nice path for us

0 · Reply

VolumePrice Dec. 17 at 6:21 PM

$CERS added 2k

0 · Reply

Greenpa Dec. 16 at 8:56 PM

$CERS Thesis remains the same. Double digit growth but RBC offers tremendous upside for outsized returns.

0 · Reply

Violenteer Dec. 15 at 2:35 PM

$CERS

0 · Reply

N8LongShort Dec. 12 at 7:12 PM

$CERS

0 · Reply

N8LongShort Dec. 12 at 2:37 PM

$CERS above 2.50 by next week

0 · Reply

SuperGreenToday Dec. 12 at 9:15 AM

$CERS Share Price: $2.16 Contract Selected: May 15, 2026 $0.5 Calls Buy Zone: $1.02 – $1.26 Target Zone: $1.81 – $2.21 Potential Upside: 68% ROI Time to Expiration: 153 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

TheMFBearKillla Dec. 11 at 11:23 PM

$CERS $IMMX $JAGX - 3DayTrigger Momentum Party Continues! 🚀 The BearKillaAlerts 3DayTrigger is HOT again. This new wave of triggers hitting with clean technical setups: CERS: 13.76% momentum move with tight consolidation IMMX: 09.66% confirmed breakout pattern JAGX: 08.27% printing higher lows All three showing convergence on hourly - moving averages stacked bullish. Volume breadth expanding. These are the kind of synergistic plays that form strong pump sequences. Dip buyers being rewarded. Path of least resistance remains UP. Support zones firm across the board. Thanks @TheMFBearKilla for staying on the BearKillaAlerts app - this is what consistent scanning pays off. Get alerts BEFORE they pop! #Momentum #TechnicalAnalysis #BullishPlaybook

0 · Reply

N8LongShort Dec. 11 at 8:05 PM

$CERS blood business is forever

0 · Reply

huma_44 Dec. 11 at 7:36 PM

$CERS hold for a year and sell above 5

1 · Reply

Violenteer Dec. 11 at 7:11 PM

$CERS Does anyone else feel like this is about to launch?

1 · Reply

N8LongShort Dec. 11 at 6:52 PM

$CERS curious on long term revenue impact but nothing but bullish https://www.businesswire.com/news/home/20251210895691/en/Cerus-Corporation-Announces-Group-Purchasing-Agreement-with-Blood-Centers-of-America

0 · Reply

N8LongShort Dec. 11 at 2:57 PM

$CERS its benchmarked $IWM any small cap growth managers may increase exposure at anytime 😂 just gotta be patient the next few weeks

0 · Reply

StockBraker Dec. 11 at 1:46 PM

$CERS

0 · Reply

Market Cap	395.70M
Revenue (ttm)	201.32M
Net Income (ttm)	-20.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-10.39%
Debt to Equity Ratio	1.37

Volume	602,700
Avg Vol	1,412,076
Day's Range	N/A - N/A
Shares Out	192.09M
Stochastic %K	23%
Beta	1.55
Analysts	Strong Sell
Price Target	$4.67